Lower riskDrug recall · FDA · Published December 5, 2022
RemedyRepack Desmopressin Tablets Recall: Subpotent Drug Risk
RemedyRepack recalls 0.2 mg Desmopressin tablets due to subpotency. Affected products have specific NDC numbers and expiration dates. Consumers should contact the manufacturer for details.
Subpotent Drug: repackaged product was recalled by the manufacturer for subpotency.
Take action
Contact the company
📍Recalling firmRemedyRepack Inc.625 Kolter Dr Ste 4 · Indiana, PA 15701-3571
✎ GovInfoNow plain-language explainer
RemedyRepack is recalling 0.2 mg Desmopressin Acetate tablets that were repackaged by them. The product was found to be subpotent, meaning it may not contain enough active ingredient to be effective as intended. This could lead to treatment failure for conditions like bleeding disorders. Read more at govinfonow.com/recall/34200-remedyrepack-desmopressin-tablets-recall-subpotent-drug-risk.
“RemedyRepack Desmopressin Tablets Recall: Subpotent Drug Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/34200-remedyrepack-desmopressin-tablets-recall-subpotent-drug-risk. Based on FDA recall #D-0077-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0077-2023%22&limit=1).
The FDA announced on December 5, 2022, that RemedyRepack Inc. recalled Desmopressin Acetate Tablet, 0.2 mg, due to subpotency concerns. The Class II recall involved nine boxes distributed to customers in Michigan.
Lot codes: B1817019-082222 (Exp. 02/24/2023), B1819127-082322 (Exp. 02/26/2023)
Quantity: 9 boxes
Distribution: Two customers in MI
The hazard
The repackaged product was recalled for subpotency, meaning the drug may not contain the expected strength of the active ingredient. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show RemedyRePack Inc. has 35 other recalls on record since February 18, 2015. Recent recalls include Clindamycin Capsules due to CGMP deviations reported on April 22, 2025 and March 24, 2025, as well as Carvedilol Tablets recalled on January 24, 2025 for N-Nitroso impurity risks. Other recent recalls of similar products include Unichem busPIRone 5mg Tablets Recall (April 13, 2026), Specialty Process Labs Thyroid Product Recall (January 16, 2026), and Major Pharmaceuticals Levothyroxine Tablets Recall (July 13, 2026).
How to tell if you have this one
Check for the product name 'Desmopressin Acetate Tablet, 0.2 mg, 100-count box' with NDC number 70518-3493-00. The expiration dates are February 24, 2023, or February 26, 2023.
Brand
RemedyRepack
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for the NDC number 70518-3493-00 on the packaging to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed in Michigan.
Listed by the agency
Not listed
FDA distribution: “Product was distributed to two different customers in MI.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Michigan.
Recall timeline
FDA terminated this recall 2 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0077-2023 (December 5, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0077-2023 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.